Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome

Brain

Volumn 140, Issue 3, 2017, Pages 669-683

  Griffin, Aliesha ^a   Hamling, Kyla R ^a   Knupp, Kelly ^b   Hong, SoonGweon ^c   Lee, Luke P ^c   Baraban, Scott C ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug screening; Epilepsy; Personalized medicine; Serotonin; Zebrafish

Indexed keywords

CLEMIZOLE; DIAZEPAM; DIZOCILPINE; LAMOTRIGINE; LORCASERIN; SEROTONIN; SEROTONIN RECEPTOR; STIRIPENTOL; TRAZODONE; ANTICONVULSIVE AGENT; BENZAZEPINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; PROTEIN BINDING; SODIUM CHANNEL NAV1.1;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING AFFINITY; CASE REPORT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DRUG BINDING; DRUG MECHANISM; FEMALE; HOMOZYGOTE; HUMAN; LOCOMOTION; MALE; MICROFLUIDICS; NONHUMAN; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SIGNAL TRANSDUCTION; VOMITING; YOUNG ADULT; ZEBRA FISH; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EPILEPSIES, MYOCLONIC; GENE EXPRESSION REGULATION; GENETICS; LARVA; METABOLISM; SEIZURES; TRANSGENIC ANIMAL; TREATMENT OUTCOME;

ADOLESCENT; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTICONVULSANTS; BENZAZEPINES; BENZIMIDAZOLES; CHILD; DISEASE MODELS, ANIMAL; EPILEPSIES, MYOCLONIC; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; LARVA; MALE; NAV1.1 VOLTAGE-GATED SODIUM CHANNEL; PROTEIN BINDING; RECEPTORS, SEROTONIN; SEIZURES; SEROTONIN; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ZEBRAFISH;

EID: 85021847915     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww342     Document Type: Article

References (54)

1. Baraban SC, Dinday MT, Hortopan GA. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun 2013; 4: 2410.
2. Baraban SC, Taylor MR, Castro PA, Baier H. Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience 2005; 131: 759–68.
3. Boothman L, Raley J, Denk F, Hirani E, Sharp T. In vivo evidence that 5-HT(2C) receptors inhibit 5-HT neuronal activity via a GABAergic mechanism. Br J Pharmacol 2006; 149: 861–9.
4. Borowicz KK, Gurdziel E, Czuczwar SJ. Trazodone reduces the anti-convulsant action of certain classical antiepileptics in the mouse maximal electroshock model. Pharmacol Rep 2012; 64: 1136–45.
5. Catterall WA, Kalume F, Oakley JC. NaV1.1 channels and epilepsy. J Physiol 2010; 588: 1849–59.
6. Ceulemans B, Schoonjans AS, Marchau F, Paelinck BP, Lagae L. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia 2016; 57: e129–34.
7. Chavan VR, Wali R, Totad R. Studies on the role of 5-HT2A and 5-HT2C receptor antagonist and effects of co-administration of Fluoxetines in regulating generalized seizures in albino rats. Al Ameen J Med Sci 2010; 3: 201–7.
8. Cheah CS, Yu FH, Westenbroek RE, Kalume FK, Oakley JC, Potter GB et al. Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome. Proc Natl Acad Sci USA 2012; 109: 14646–51.
9. Chiron C, Marchand MC, Tran A, Rey E, d’Athis P, Vincent J et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO Study Group. Lancet 2000; 356: 1638–42.
10. Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, Chevenet F et al. Phylogeny.fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res 2008; 36: W465–9.
11. Detyniecki K, Hirsch LJ. Cannabidiol for epilepsy: trying to see through the haze. Lancet Neurol 2016; 15: 235–7.
12. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016; 15: 270–8.
13. Dinday MT, Baraban SC. Large-scale phenotype-based antiepileptic drug screening in a zebrafish model of dravet syndrome(1,2,3). eNeuro 2015; 2.
14. Douglas JG, Munro JF, Kitchin AH, Muir AL, Proudfoot AT. Pulmonary hypertension and fenfluramine. Br Med J (Clin Res Ed) 1981; 283: 881–3.
15. Dravet C. The core Dravet syndrome phenotype. Epilepsia 2011; 52 (Suppl 2): 3–9.
16. Dunoyer M. Accelerating access to treatments for rare diseases. Nat Rev Drug Discov 2011; 10: 475–6.
17. Dutton SB, Makinson CD, Papale LA, Shankar A, Balakrishnan B, Nakazawa K, et al. Preferential inactivation of Scn1a in parvalbu-min interneurons increases seizure susceptibility. Neurobiol Dis 2013; 49: 211–20.
18. Escayg A, Goldin AL. Sodium channel SCN1A and epilepsy: mutations and mechanisms. Epilepsia 2010; 51: 1650–8.
19. Finkelstein M, Kromer CM, Sweeney SA, Delahunt CS. Some aspects of the pharmacology of clemizole hydrochloride. J Am Pharm Assoc Am Pharm Assoc 1960; 49: 18–22.
20. Gharedaghi MH, Seyedabadi M, Ghia JE, Dehpour AR, Rahimian R. The role of different serotonin receptor subtypes in seizure susceptibility. Exp Brain Res 2014; 232: 347–67.
21. Guiard BP, Di Giovanni G. Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link?. Front Pharmacol 2015; 6: 46.
22. Han S, Tai C, Westenbroek RE, Yu FH, Cheah CS, Potter GB, et al. Autistic-like behaviour in Scn1a + /- mice and rescue by enhanced GABA-mediated neurotransmission. Nature 2012; 489: 385–90.
23. Hodgkin AL, Huxley AF. A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol 1952; 117: 500–44.
24. Hong S, Lee P, Baraban SC, Lee LP. A novel long-term, multi-channel and non-invasive electrophysiology platform for Zebrafish. Sci Rep 2016; 6: 28248.
25. Jacques AA, Fuchs VH. Clinical evaluation of clemizole in allergic rhinitis. Int Rec Med 1960; 173: 88–91.
26. Jiao J, Yang Y, Shi Y, Chen J, Gao R, Fan Y, et al. Modeling Dravet syndrome using induced pluripotent stem cells (iPSCs) and directly converted neurons. Hum Mol Genet 2013; 22: 4241–52.
27. Kalume F, Yu FH, Westenbroek RE, Scheuer T, Catterall WA. Reduced sodium current in Purkinje neurons from Nav1.1 mutant mice: implications for ataxia in severe myoclonic epilepsy in infancy. J Neurosci 2007; 27: 11065–74.
28. Kearney J. Sudden unexpected death in dravet syndrome. Epilepsy Curr 2013; 13: 264–5.
29. Kumar MG, Rowley S, Fulton R, Dinday MT, Baraban SC, Patel M. Altered glycolysis and mitochondrial respiration in a zebrafish model of dravet syndrome. eNeuro 2016; 3.
30. Lambe EK, Fillman SG, Webster MJ, Shannon Weickert C. Serotonin receptor expression in human prefrontal cortex: balancing excitation and inhibition across postnatal development. PLoS One 2011; 6: e22799.
31. Li BM, Liu XR, Yi YH, Deng YH, Su T, Zou X, et al. Autism in Dravet syndrome: prevalence, features, and relationship to the clinical characteristics of epilepsy and mental retardation. Epilepsy Behav 2011; 21: 291–5.
32. Liu S, Bubar MJ, Lanfranco MF, Hillman GR, Cunningham KA. Serotonin2C receptor localization in GABA neurons of the rat medial prefrontal cortex: implications for understanding the neurobiology of addiction. Neuroscience 2007; 146: 1677–88.
33. Liu Y, Lopez-Santiago LF, Yuan Y, Jones JM, Zhang H, O’Malley HA, et al. Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism. Ann Neurol 2013; 74: 128–39.
34. MacRae CA, Peterson RT. Zebrafish as tools for drug discovery. Nat Rev Drug Discov 2015; 14: 721–31.
35. Maj J, Palider W, Rawlow. Trazodone, a central serotonin antagonist and agonist. J Neural Transm 1979; 44: 237–48.
36. Marcoli M, Maura G, Tortarolo M, Raiteri M. Trazodone is a potent agonist at 5-HT2C receptors mediating inhibition of the N-methyl-D-aspartate/nitric oxide/cyclic GMP pathway in rat cerebellum. J Pharmacol Exp Ther 1998; 285: 983–6.
37. Meltzer HY, Roth BL. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest 2013; 123: 4986–91.
38. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005; 66: 469–76.
39. Miyata I, Saegusa H, Sakurai M. Seizure-modifying potential of histamine H1 antagonists: a clinical observation. Pediatr Int 2011; 53: 706–8.
40. Nishimura T, Hu Y, Wu M, Pham E, Suemizu H, Elazar M. et al. Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther 2013; 344: 388–96.
41. Oakley JC, Kalume F, Yu FH, Scheuer T, Catterall WA. Temperature- and age-dependent seizures in a mouse model of severe myoclonic epilepsy in infancy. Proc Natl Acad Sci USA 2009; 106: 3994–9.
42. Parker WE, Orlova KA, Parker WH, Birnbaum JF, Krymskaya VP, Goncharov DA, et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci Transl Med 2013; 5: 182ra53.
43. Peitsaro N, Sundvik M, Anichtchik OV, Kaslin J, Panula P. Identification of zebrafish histamine H1, H2 and H3 receptors and effects of histaminergic ligands on behavior. Biochem Pharmacol 2007; 73: 1205–14.
44. Perez J, Chiron C, Musial C, Rey E, Blehaut H, d’Athis P, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 1999; 40: 1618–26.
45. Schoonheim PJ, Arrenberg AB, Del Bene F, Baier H. Optogenetic localization and genetic perturbation of saccade-generating neurons in zebrafish. J Neurosci 2010; 30: 7111–20.
46. Schutte RJ, Schutte SS, Algara J, Barragan EV, Gilligan J, Staber C, et al. Knock-in model of Dravet syndrome reveals a constitutive and conditional reduction in sodium current. J Neurophysiol 2014; 112: 903–12.
47. Sourbron J, Schneider H, Kecskes A, Liu Y, Buening EM, Lagae L, et al. Serotonergic modulation as effective treatment for dravet syndrome in a zebrafish mutant model. ACS Chem Neurosci 2016; 7: 588–98.
48. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009; 14: 536–46.
49. Tai C, Abe Y, Westenbroek RE, Scheuer T, Catterall WA. Impaired excitability of somatostatin- and parvalbumin-expressing cortical interneurons in a mouse model of Dravet syndrome. Proc Natl Acad Sci USA 2014; 111: E3139–48.
50. Teixeira-Castro A, Jalles A, Esteves S, Kang S, da Silva Santos L, Silva-Fernandes A, et al. Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain 2015; 138: 3221–37.
51. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008; 325: 577–87.
52. Winter MJ, Redfern WS, Hayfield AJ, Owen SF, Valentin JP, Hutchinson TH. Validation of a larval zebrafish locomotor assay for assessing the seizure liability of early-stage development drugs. J Pharmacol Toxicol Methods 2008; 57: 176–87.
53. Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F, Burton KA, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006; 9: 1142–9.
54. Zierz P, Greither H. Clinical evaluation of allercur, a new antihista-minic [Article in Undetermined Language]. Arztl Wochensch 1952; 7: 704–7.